Listing 1 - 10 of 15 | << page >> |
Sort by
|
Choose an application
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact
Medicine --- Immunology --- HIV --- cancer --- ART --- immunotherapy --- immune surveillance --- immune checkpoint blockade --- inflammation --- CAR T cells
Choose an application
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact
Medicine --- Immunology --- cancer --- immunotherapy --- radiotherapy --- antiangiogenic therapy --- immune checkpoint blockade (ICB) --- cancer vaccine
Choose an application
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact
Medicine --- Immunology --- HIV --- cancer --- ART --- immunotherapy --- immune surveillance --- immune checkpoint blockade --- inflammation --- CAR T cells
Choose an application
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact
Medicine --- Immunology --- cancer --- immunotherapy --- radiotherapy --- antiangiogenic therapy --- immune checkpoint blockade (ICB) --- cancer vaccine
Choose an application
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact
HIV --- cancer --- ART --- immunotherapy --- immune surveillance --- immune checkpoint blockade --- inflammation --- CAR T cells
Choose an application
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact
cancer --- immunotherapy --- radiotherapy --- antiangiogenic therapy --- immune checkpoint blockade (ICB) --- cancer vaccine
Choose an application
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.
Medicine --- Clinical & internal medicine --- oncolytic viruses --- melanoma --- immunotherapy --- checkpoint inhibitors --- combinatory therapy --- reovirus --- oncolytic virus --- adenovirus --- oncolytic --- virotherapy --- targeting --- immunogenic cell death --- αvβ6 integrin --- oncolytic adenovirus --- cancer immunotherapy --- multi-stage --- immunostimulatory --- arming --- HSV-1 --- clinical trials --- newcastle disease virus --- NDV --- cancer --- immune checkpoint inhibitor --- PD-1 --- PD-L1 --- CTLA-4 --- type I interferon --- herpes simplex virus --- retargeted virus --- tropism retargeting --- tumor --- checkpoint inhibitor --- vaccination --- antigen-agnostic vaccination --- HER2 --- parvovirus --- tumor microenvironment --- combination therapy --- glioblastoma --- pancreatic cancer --- colorectal cancer --- measles virus --- vector engineering --- immune checkpoint blockade --- antitumor immune response --- delivery --- genetic modification --- biomarkers --- personalized oncolyticvirotherapy --- class I HLA --- immunosurveillance --- immunoediting --- oncogenic signaling --- RAS --- DNA methyltransferase inhibitor (DNMTi) --- viral mimicry --- epigenetic silencing --- adoptive T cell therapy --- CAR T cell --- pancreatic ductal adenocarcinoma --- vesicular stomatitis virus --- small molecule --- cancer immune therapy --- cancer therapy --- n/a
Choose an application
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.
Medicine --- Clinical & internal medicine --- oncolytic viruses --- melanoma --- immunotherapy --- checkpoint inhibitors --- combinatory therapy --- reovirus --- oncolytic virus --- adenovirus --- oncolytic --- virotherapy --- targeting --- immunogenic cell death --- αvβ6 integrin --- oncolytic adenovirus --- cancer immunotherapy --- multi-stage --- immunostimulatory --- arming --- HSV-1 --- clinical trials --- newcastle disease virus --- NDV --- cancer --- immune checkpoint inhibitor --- PD-1 --- PD-L1 --- CTLA-4 --- type I interferon --- herpes simplex virus --- retargeted virus --- tropism retargeting --- tumor --- checkpoint inhibitor --- vaccination --- antigen-agnostic vaccination --- HER2 --- parvovirus --- tumor microenvironment --- combination therapy --- glioblastoma --- pancreatic cancer --- colorectal cancer --- measles virus --- vector engineering --- immune checkpoint blockade --- antitumor immune response --- delivery --- genetic modification --- biomarkers --- personalized oncolyticvirotherapy --- class I HLA --- immunosurveillance --- immunoediting --- oncogenic signaling --- RAS --- DNA methyltransferase inhibitor (DNMTi) --- viral mimicry --- epigenetic silencing --- adoptive T cell therapy --- CAR T cell --- pancreatic ductal adenocarcinoma --- vesicular stomatitis virus --- small molecule --- cancer immune therapy --- cancer therapy --- n/a
Choose an application
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities.
oncolytic viruses --- melanoma --- immunotherapy --- checkpoint inhibitors --- combinatory therapy --- reovirus --- oncolytic virus --- adenovirus --- oncolytic --- virotherapy --- targeting --- immunogenic cell death --- αvβ6 integrin --- oncolytic adenovirus --- cancer immunotherapy --- multi-stage --- immunostimulatory --- arming --- HSV-1 --- clinical trials --- newcastle disease virus --- NDV --- cancer --- immune checkpoint inhibitor --- PD-1 --- PD-L1 --- CTLA-4 --- type I interferon --- herpes simplex virus --- retargeted virus --- tropism retargeting --- tumor --- checkpoint inhibitor --- vaccination --- antigen-agnostic vaccination --- HER2 --- parvovirus --- tumor microenvironment --- combination therapy --- glioblastoma --- pancreatic cancer --- colorectal cancer --- measles virus --- vector engineering --- immune checkpoint blockade --- antitumor immune response --- delivery --- genetic modification --- biomarkers --- personalized oncolyticvirotherapy --- class I HLA --- immunosurveillance --- immunoediting --- oncogenic signaling --- RAS --- DNA methyltransferase inhibitor (DNMTi) --- viral mimicry --- epigenetic silencing --- adoptive T cell therapy --- CAR T cell --- pancreatic ductal adenocarcinoma --- vesicular stomatitis virus --- small molecule --- cancer immune therapy --- cancer therapy --- n/a
Choose an application
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue.
Medicine --- NKG2D --- CAR T --- IL-7 --- prostate cancer --- cell therapy --- CD19-CAR-T --- B cell aplasia --- KIR --- PD-1 --- inhibitory CAR --- tumor-infiltrating lymphocytes --- tumor microenvironment --- immunotherapy --- NK cells --- cancer stem cells (CSCs) --- antibody-dependent cellular cytotoxicity (ADCC) --- differentiation --- cytotoxicity --- IFN-γ --- osteoclasts --- MICA/B mAb --- DNA methylation --- RNA methylation --- S-adenosylmethionine (SAM) --- cancer --- innate immunity --- adaptive immunity --- T cells --- m6A --- PD-L1 --- resistance --- immune checkpoints --- cancer vaccine --- combination immunotherapy --- TCR diversity --- organ transplantation --- carcinoma --- epidemiologic studies --- immunosuppression --- CTLA-4 --- Treg cells --- immune checkpoint inhibitors --- CD28 --- antigen-presenting cells --- IL15 --- colon cancer --- melanoma --- uveal --- BAP1 --- anti-PD-1 --- anti-CTLA-4 --- TIL --- classical and endemic Kaposi Sarcoma --- systemic treatment --- multi-state modelling --- treatment free interval --- chemotherapy --- interferon --- triple negative breast cancer --- immunomodulation --- bispecific antibody --- sortase A --- chemo-enzymatic approach --- anti-CD20 antibody --- Fab --- BiFab --- colorectal cancer --- dendritic cells --- Atypical Chemokine Receptor 4 (ACKR4) --- T-cell priming --- immune checkpoint blockade --- primary liver cancer --- kynurenine pathway --- immune evasion --- indoleamine 2,3 dioxygenase 1 --- tryptophan 2,3 dioxygenase 2 --- IDO inhibitor --- antigen presenting cells --- n/a
Listing 1 - 10 of 15 | << page >> |
Sort by
|